BioCentury
ARTICLE | Company News

CHMP recommendations include two new HCV combos

June 23, 2017 10:38 PM UTC

On Friday, EMA's CHMP recommended approval of a basket of therapies, including two new combinations to treat HCV infection.

The committee recommended approval of Maviret glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV) to treat chronic HCV infection in adults. It is a fixed-dose combination of glecaprevir (ABT-493), a next-generation HCV NS3/4A protease inhibitor, and pibrentasvir (ABT-530), a next-generation HCV NS5A protein inhibitor. The combo is also under Priority Review by FDA...